Evercore ISI Reaffirms Their Buy Rating on uniQure NV (QURE)
Evercore ISI analyst Joshua Schimmer maintained a Buy rating on uniQure NV (QURE) yesterday and set a price target of $79. The company’s shares closed last Monday at $56.24.
“We continue to believe QURE’s approach may be differentiated by targeting exon 1. Updates from IONS/Roche expected in 2H19 and 2020 will be important to track for read-through to QURE’s development pathway.”
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.8% and a 50.8% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Mirum Pharmaceuticals Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $99.40, implying a 90.2% upside from current levels. In a report issued on July 30, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $82.49 and a one-year low of $21.98. Currently, uniQure NV has an average volume of 745.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.